Angioedema News and Research

RSS
Angioedema is the rapid swelling (edema) of the dermis, subcutaneous tissue, mucosa and submucosal tissues. It is very similar to urticaria, but urticaria, commonly known as hives, occurs in the upper dermis.
FDA approves Ruconest for treatment of acute attacks in adolescent patients with HAE

FDA approves Ruconest for treatment of acute attacks in adolescent patients with HAE

Fabry disease awareness: an interview with Dr. Hartmann Wellhoefer, Head of Medical Affairs, Rare Disease, Shire

Fabry disease awareness: an interview with Dr. Hartmann Wellhoefer, Head of Medical Affairs, Rare Disease, Shire

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

SYNERA can help prevent needle stick pain associated with superficial IVs

SYNERA can help prevent needle stick pain associated with superficial IVs

Endo acquires worldwide rights to Zogenix' sumatriptan injection

Endo acquires worldwide rights to Zogenix' sumatriptan injection

Investigators find effective treatment for life-threatening angioedema attacks in ED

Investigators find effective treatment for life-threatening angioedema attacks in ED

UCB announces results from PRECiSE clinical trial of Cimzia in patients with Crohn's disease

UCB announces results from PRECiSE clinical trial of Cimzia in patients with Crohn's disease

Genmab/GSK receive FDA sBLA approval for Arzerra in combination with chlorambucil for treatment of CLL

Genmab/GSK receive FDA sBLA approval for Arzerra in combination with chlorambucil for treatment of CLL

FDA approves expanded use Dyax’s KALBITOR in treatment of acute hereditary angioedema

FDA approves expanded use Dyax’s KALBITOR in treatment of acute hereditary angioedema

Safeguard Scientifics reports net income of $24 million for fourth quarter 2013

Safeguard Scientifics reports net income of $24 million for fourth quarter 2013

Dyax reports total revenues of $16.9 million for fourth quarter 2013

Dyax reports total revenues of $16.9 million for fourth quarter 2013

CSL Behring enrolls first patient in phase III study of C1-INH for prevention of HAE attacks

CSL Behring enrolls first patient in phase III study of C1-INH for prevention of HAE attacks

Amneal launches generic Esomeprazole strontium delayed-release capsules 49.3 mg

Amneal launches generic Esomeprazole strontium delayed-release capsules 49.3 mg

BioCryst receives $2.5M to advance development of BCX4430 for Marburg virus disease treatment

BioCryst receives $2.5M to advance development of BCX4430 for Marburg virus disease treatment

Biocryst seeks FDA NDA approval for Peramivir to treat influenza

Biocryst seeks FDA NDA approval for Peramivir to treat influenza

FDA approves Baxter's FEIBA for prophylactic treatment of hemophilia patients with inhibitors

FDA approves Baxter's FEIBA for prophylactic treatment of hemophilia patients with inhibitors

Amneal's Esomeprazole Strontium 49.3 mg delayed-release capsules now available for GERD patients

Amneal's Esomeprazole Strontium 49.3 mg delayed-release capsules now available for GERD patients

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

EMA expands administration options for Hizentra

EMA expands administration options for Hizentra

Forest Laboratories to acquire exclusive rights in the U.S. for Saphris sublingual tablets

Forest Laboratories to acquire exclusive rights in the U.S. for Saphris sublingual tablets